Catalent and Bend to offer oral drug formulation services
Aiming to provide a more efficient path to market
Catalent Pharma Solutions has agreed with Bend Research to offer integrated solutions for the development and manufacture of specialised multiparticulate oral controlled-release products.
The two firms are developing joint operations and technology transfer protocols to provide a more seamless process for clients.
The companies’ combined expertise in formulation development and Catalent's analytical/CMC, solid state optimisation, clinical and commercial supply services will provide pharmaceutical companies with optimal dosage forms and a more efficient path to market.
Rod Ray, ceo of Bend Research, said: ‘Our integrated approach is geared toward complex, multiparticulate controlled-release products, which traditionally have presented a high scale-up risk when they are transferred to commercial manufacturing sites.
‘This partnership with Catalent will provide an efficient pathway for these medicines from early development to commercialisation.’
Ian Muir, president of Catalent’s Modified Release Technologies business, added that Bend’s laboratory scale modelling expertise would enhance and increase the efficiencies that Catalent will provide to customers to bring difficult to formulate and manufacture controlled-release compounds to market faster.’
